| Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis (NCT02162472) | Northwestern University | 2015-07-01 |
| Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis (NCT02397382) | Janssen Research & Development, LLC | 2015-06-18 |
| Trial to Evaluate Topical C-82 in a Psoriasis Plaque Test (NCT02432027) | Prism Pharma Co., Ltd. | 2015-06-01 |
| Autologous Cytokine Induced Killer Cells (CIK) for Patients With Severe Psoriasis (NCT01894373) | Chinese PLA General Hospital | 2015-06-01 |
| MYL-1401A Efficacy and Safety Comparability Study to Humira® (NCT02714322) | Mylan Inc. | 2015-06-01 |
| Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis (NCT02595970) | Novartis Pharmaceuticals | 2015-05-20 |
| The Association Between Psoriasis and Intestinal Bacterial Population (NCT02417792) | Assuta Hospital Systems | 2015-05-14 |
| A Randomized Control Trial of Patient-initiated Hospital Follow-up for Patients With Psoriasis (NCT02382081) | University Hospital, Gentofte, Copenhagen | 2015-05-02 |
| Luma Light System Proof of Concept Study in Subjects With Mild to Moderate Psoriasis (NCT02447068) | Illumicure Inc | 2015-05-01 |
| Single Ascending Dose Study of PRX003 in Healthy Subjects (NCT02458677) | Prothena Biosciences Limited | 2015-05-01 |
| Identification of New Prognostic Markers in Psoriatic Arthritis (NCT03455166) | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio | 2015-05-01 |
| Intervention Study to Evaluate a Probiotic in Mild to Moderate Psoriasis Patients (NCT02576197) | Biopolis S.L. | 2015-05-01 |
| A Trial That Compound Clobetasol Propionate Ointment Treats Patients With Mild to Moderate Psoriasis Vulgaris. (NCT02733874) | First Hospital of China Medical University | 2015-04-01 |
| A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis (NCT02387801) | Eli Lilly and Company | 2015-04-01 |
| Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis. (NCT02474082) | Novartis Pharmaceuticals | 2015-04-01 |
| Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis (NCT03058744) | Bausch Health Americas, Inc. | 2015-04-01 |
| The CorEvitas Psoriasis (PSO) Registry (NCT02707341) | CorEvitas | 2015-04-01 |
| Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients (NCT02413801) | University of Rochester | 2015-03-19 |
| Disease Trajectories and Anti-cytokine Response Signatures in Atopic Dermatitis and Psoriasis (NCT03361215) | University Hospital Schleswig-Holstein | 2015-03-16 |
| Sleep, Circadian Rhythm & Skin Health (NCT02457000) | University Hospitals Cleveland Medical Center | 2015-03-01 |
| Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO) (NCT02346240) | UCB Biopharma S.P.R.L. | 2015-02-11 |
| Diabetes and Psoriasis (NCT02366273) | University of Pavia | 2015-02-01 |
| Efficacy of Novel Drug-combinations for Relief of Psoriasis (NCT02394301) | Medimix Specialty Pharmacy, LLC | 2015-02-01 |
| Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers (NCT02362789) | Novartis Pharmaceuticals | 2015-01-04 |
| A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10 (NCT02322086) | Provectus Pharmaceuticals | 2015-01-01 |
| Safety and Efficacy Study of Etanercept (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis (NCT02701205) | Shanghai Celgen Bio-Pharmaceutical Co.,Ltd | 2015-01-01 |
| An Observational Monocentric Study Investigating the Association Between Trough Serum Levels of Etanercept, Antibodies Towards Etanercept and Its Effectiveness in Psoriasis Patients (NCT02322580) | Universitaire Ziekenhuizen KU Leuven | 2015-01-01 |
| An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) (NCT02326298) | UCB Biopharma S.P.R.L. | 2014-12-16 |
| A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) (NCT02326272) | UCB Biopharma S.P.R.L. | 2014-12-15 |
| Psoriasis Microbiome and Phototherapy (NCT02552316) | University of Pennsylvania | 2014-12-01 |
| A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis (NCT02207231) | Janssen Research & Development, LLC | 2014-11-26 |
| Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis (NCT02203851) | AbbVie | 2014-11-20 |
| A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis (NCT02295865) | Janssen Research & Development, LLC | 2014-11-17 |
| A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment (NCT02207244) | Janssen Research & Development, LLC | 2014-11-03 |
| Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate (NCT02313922) | Zhejiang University | 2014-11-01 |
| Etanercept Survival in Elderly Population (NCT02503059) | Fundación Pública Andaluza Progreso y Salud | 2014-11-01 |
| PASIMAT: Automatic Measure of PASI (NCT02808559) | Centre Hospitalier Universitaire de Nice | 2014-11-01 |
| Apremilast Pregnancy Exposure Registry (NCT02775500) | University of California, San Diego | 2014-11-01 |
| Recirculating Memory T Cells in the Pathogenesis of Psoriatic Arthritis and Cutaneous Psoriasis (NCT03374527) | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio | 2014-10-16 |
| A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab (NCT02203032) | Janssen Research & Development, LLC | 2014-10-07 |
| Cytokines and Vascular Inflammation in Psoriasis (NCT02305953) | Innovaderm Research Inc. | 2014-10-01 |
| Randomized, Blinded, Sham-controlled Trial of Acupuncture for the Management of Joint Pain in Patients With Psoriasis (NCT02047851) | University Hospital, Gentofte, Copenhagen | 2014-10-01 |
| Effect of Vitamin D Supplementation on Metabolic Parameters of Patients With Psoriasis (NCT02271971) | Pontificia Universidad Catolica de Chile | 2014-10-01 |
| Comparison of the Frequency of Subclinic Synovitis in the Distal Interphalangeal Joints of the Hand in Psoriasis Patients (NCT04750993) | Ufuk University | 2014-10-01 |
| Tolerability, Safety and Pharmacokinetic Study of Humanized Anti-CD6 Monoclonal Antibody Injection in Chinese Psoriasis (NCT02649270) | Biotech Pharmaceutical Co., Ltd. | 2014-10-01 |
| A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of Brodalumab (NCT02173392) | Bausch Health Americas, Inc. | 2014-09-01 |
| Anti-psoriatic Effect of TL01 Light Therapy (NCT02599415) | University of Aberdeen | 2014-09-01 |
| Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study (NCT02196701) | AbbVie | 2014-08-05 |
| Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects (NCT02156466) | Merck KGaA, Darmstadt, Germany | 2014-08-01 |
| Comparison Study of Psoriasis Severity Assessment Tools (NCT02655705) | Seoul National University Hospital | 2014-08-01 |
| A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Intravenous (IV) Dose of GSK2831781 in Healthy Volunteers and Patients With Plaque Psoriasis (NCT02195349) | GlaxoSmithKline | 2014-07-30 |
| Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U) (NCT02187172) | University of Pennsylvania | 2014-07-01 |
| A Intra-individual Comparison to Investigate the Efficacy and the Safety of LAS41004 Formulation in Mild to Moderate Psoriasis (NCT02180464) | Almirall, S.A. | 2014-06-01 |
| A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis (NCT02173301) | Dr. Reddy's Laboratories Limited | 2014-06-01 |
| An Open-label Controlled Trial: Effectiveness of Balneotherapy in Palmoplantar Psoriasis and Contact Dermatitis. (NCT06458868) | Ankara University | 2014-06-01 |
| Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis (NCT02144857) | University of Athens | 2014-05-30 |
| DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis (NCT02131324) | Promius Pharma, LLC | 2014-05-08 |
| Safety and Efficacy of Etanercept in Patients With Psoriasis (NCT02258282) | Chengdu PLA General Hospital | 2014-05-01 |
| Individualized Medical Training and Calcipotriol and Betamethasone Dipropionate Gel in Plaque Psoriasis (NCT02489643) | Catholic University of the Sacred Heart | 2014-05-01 |
| Reduction of Pain Caused by Biologic Drugs in Psoriasis (NCT02168244) | Icahn School of Medicine at Mount Sinai | 2014-05-01 |
| Regulation of Inflammatory Genes in Psoriasis (NCT03125655) | University of Alabama at Birmingham | 2014-04-22 |
| Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial. (NCT01991197) | University College Dublin | 2014-04-01 |
| Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab (NCT02559622) | Novartis Pharmaceuticals | 2014-04-01 |
| Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris (NCT01999868) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-03-19 |
| The Immunological Basis for Treatment Resistance to Anti-TNF Treatments (NCT01971346) | University of Michigan | 2014-03-13 |
| An Exploratory Genetic Study in Participants With Psoriasis (NCT02155192) | Janssen Research & Development, LLC | 2014-03-01 |
| Bioequivalence and Pharmacokinetic Study of Prurisol™ and Abacavir Sulfate in Healthy Volunteers (NCT02101216) | Cellceutix Corporation | 2014-03-01 |
| Efficacy, Tolerability and Safety of LAS41004 Formulations in a Psoriasis Plaque Test (NCT02111499) | Almirall, S.A. | 2014-03-01 |
| BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab (NCT02054481) | Boehringer Ingelheim | 2014-02-01 |
| Therapeutic Drug Monitoring of Adalimumab in Psoriasis Patients (NCT02147600) | University Hospital, Ghent | 2014-01-09 |
| Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases (NCT01988506) | Assistance Publique - Hôpitaux de Paris | 2014-01-06 |
| T and B Cell Responses in Autoimmune Diseases (NCT01947036) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-01-01 |
| Comparative Analysis of Small and Large Plaque Psoriasis (NCT01920906) | Rockefeller University | 2014-01-01 |
| Effectiveness of Artificial Balneotherapy, Phototherapy and Artificial Balneophototherapy in the Treatment of Psoriasis (NCT02713711) | Universidad Católica del Maule | 2013-12-01 |
| A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis (NCT01815424) | Pfizer | 2013-12-01 |
| Comparing Mindfulness Based Cognitive Therapy and Mindfulness Based Self-compassion Therapy in a Psoriasis Sample (NCT02122978) | St Vincent's University Hospital, Ireland | 2013-11-01 |
| A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis (NCT01947491) | Primus Pharmaceuticals | 2013-11-01 |
| Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP) (NCT02347501) | University College Dublin | 2013-11-01 |
| Efficacy and Safety Study of Calcipotriol Betamethasone Plus Calcipotriol in Sequential Therapy to Psoriasis (NCT02191007) | Xijing Hospital | 2013-11-01 |
| A Comparison of DFD01 Spray Versus Vehicle Spray in Subjects With Moderate Psoriasis (NCT01967069) | Primus Pharmaceuticals | 2013-11-01 |
| Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project (NCT02103361) | University of California, San Diego | 2013-11-01 |
| Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis (NCT01970488) | Amgen | 2013-10-18 |
| Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants. (NCT01961609) | Novartis Pharmaceuticals | 2013-10-09 |
| A Safety and Efficacy Study of DRM02 in Subjects With Plaque Psoriasis (NCT01993433) | Dermira, Inc. | 2013-10-01 |
| Efficacy and Safety Study of Subcutaneous Secukinumab in Treatment of Subjects With Moderate to Severe Chronic Plaque-type Psoriasis as Compared to Etanercept and Placebo. (NCT01900782) | Novartis Pharmaceuticals | 2013-10-01 |
| A Safety Study of Mirikizumab (LY3074828) (NCT01947933) | Eli Lilly and Company | 2013-10-01 |
| Excimer Laser, Serum Markers & Psoriasis (NCT02165657) | University Hospitals Cleveland Medical Center | 2013-09-01 |
| Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects (NCT01937260) | Bausch Health Americas, Inc. | 2013-09-01 |
| Clinical Assessment and Psychosocial Impact of Psoriasis (NCT01964443) | Janssen Pharmaceutica N.V., Belgium | 2013-09-01 |
| Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) (NCT01952015) | Novartis Pharmaceuticals | 2013-08-21 |
| Study to Assess Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Effect of UCB5857 in Healthy & Psoriatic Subject (NCT02303509) | UCB Pharma | 2013-08-01 |
| Photocil (Topical) for the Treatment of Psoriasis Vulgaris (NCT01916629) | Applied Biology, Inc. | 2013-08-01 |
| Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis (NCT01908595) | Maruho North America Inc. | 2013-08-01 |
| A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunogenicity, and Pharmacodynamics (PD) of GSK2800528 in Healthy Subjects. (NCT01899755) | GlaxoSmithKline | 2013-07-10 |
| Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis (NCT01988103) | Amgen | 2013-07-09 |
| At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions (NCT01931644) | Sanguine Biosciences | 2013-07-01 |
| Efficacy Study of Trichuris Suis Ova to Treat Chronic Plaque Psoriasis (NCT01948271) | Tufts Medical Center | 2013-07-01 |
| Evaluation of Vitamin D Levels in Psoriasis Patients (NCT01903317) | University of California, Irvine | 2013-06-01 |
| Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis (NCT01873677) | Maruho North America Inc. | 2013-06-01 |
| Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis (NCT01878461) | Maruho North America Inc. | 2013-06-01 |